Company intelligence / Profile preview
Cortene Inc.
Burlingame, California, United Statescorteneinc.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
Completed a Phase 2 proof-of-concept clinical trial (InTiME) for ME/CFS using CT38, showing sustained symptom improvement. At an infusion rate of 0.03 μg/kg/h, mean total daily symptom score improved by 26% (p < 0.01, n = 7). The company is planning trials for Parkinson's and Alzheimer's.
- Therapeutic areas
- NephrologyImmunologyNeurologyInfectious Diseases
- Modalities
- Peptide-based treatments
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Bateman Horne Center (for clinical trials)
Beyond the preview
Go deeper on Cortene Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cortene Inc..